GO:0001918 farnesylated protein binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001918 (farnesylated protein binding) is a molecular function defined as binding to a farnesylated protein, i.e., a protein carrying a 15-carbon farnesyl isoprenoid lipid attached via a thioether bond to a cysteine residue.
• Farnesylation is catalyzed by protein farnesyltransferase (FTase), a heterodimeric enzyme that transfers a farnesyl group from farnesyl diphosphate to C-terminal CaaX motifs of substrate proteins.
• Farnesylated proteins include small GTPases such as Rheb, Ras family members, and guanylate-binding proteins (GBPs), where the lipid modification drives membrane association and function.
• Farnesylated protein binding underlies key cellular processes including membrane targeting, protein-protein interactions, and polymerization of farnesylated human GBP1.
• Dysregulation of farnesylated protein interactions is implicated in diseases such as pulmonary hypertension and acute myelogenous leukemia, where farnesyltransferase inhibitors (e.g., tipifarnib) show therapeutic effects.
• Research on farnesylated protein binding employs biochemical binding assays, fluorescence microscopy, and CRISPR-based gene editing to dissect interaction interfaces and cellular consequences.
Description
Farnesylated protein binding (GO:0001918) is a molecular function that describes the selective interaction of a protein or other molecule with a farnesylated protein partner. Farnesylation is a post-translational modification in which a 15-carbon farnesyl isoprenoid group is covalently attached to a cysteine residue near the C-terminus of a target protein, typically within a CaaX motif. This modification increases hydrophobicity and promotes membrane association, enabling farnesylated proteins to participate in signaling, trafficking, and assembly processes. The ability to bind farnesylated proteins is therefore central to how cells decode and regulate isoprenylated protein signals. Researchers study GO:0001918 to understand mechanisms of membrane targeting, protein complex formation, and the pharmacological consequences of blocking farnesylation. The term is particularly relevant to small GTPases such as Rheb and Ras, whose farnesylation is required for their biological activity and whose aberrant interactions contribute to cancer and cardiovascular disease. Farnesylated human guanylate-binding protein 1 (hGBP1) provides a tractable model for studying how farnesylated protein binding drives polymerization and membrane binding. In plants, farnesylated protein binding is exemplified by the interaction between acyl-CoA-binding protein ACBP2 and the heavy-metal-binding farnesylated protein AtFP6, highlighting the evolutionary conservation of this function. This article integrates authoritative QuickGO annotation with verified PubMed literature to provide a research-grade overview of GO:0001918, its molecular mechanism, associated genes, disease relevance, and experimental strategies.
farnesylated protein binding At A Glance
| GO ID | GO:0001918 |
|---|---|
| GO term | farnesylated protein binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to a farnesylated protein. |
| Major function | Recognition and interaction with proteins carrying a farnesyl isoprenoid modification, enabling membrane association, complex formation, and signaling. |
| Related modification | Farnesylation, a post-translational lipid modification catalyzed by protein farnesyltransferase. |
| Example interactors | Farnesylated small GTPases (e.g., Rheb), guanylate-binding proteins (e.g., hGBP1), and plant ACBP2-AtFP6 pair. |
| Disease relevance | Pulmonary hypertension, acute myelogenous leukemia, and other conditions linked to farnesylated protein signaling. |
What Is GO:0001918?
According to the Gene Ontology, GO:0001918 (farnesylated protein binding) is defined as binding to a farnesylated protein. In other words, it is the molecular function of selectively and non-covalently interacting with a protein that carries a farnesyl lipid modification. This function is distinct from enzymatic activity that adds the farnesyl group; rather, it describes the recognition event that occurs after farnesylation has taken place. The binding may involve the farnesyl moiety itself, the modified cysteine-containing region, or a conformational epitope created by farnesylation. Farnesylated protein binding is essential for processes such as membrane recruitment, protein complex assembly, and signal transduction.
Why Is farnesylated protein binding Important in Cell Biology?
Farnesylated protein binding is important because it governs how cells interpret the presence of farnesylated proteins, which are key mediators of membrane-associated signaling and trafficking. Many farnesylated proteins, including small GTPases such as Rheb and Ras, require farnesylation for their localization and activity, and the binding events that recognize these modified proteins are critical for downstream cellular responses. Pharmacological inhibition of farnesylation with farnesyltransferase inhibitors such as tipifarnib alters these interactions and has therapeutic potential in diseases like pulmonary hypertension and leukemia. Moreover, farnesylated protein binding is not limited to mammals; plant systems use analogous interactions to regulate heavy-metal responses, underscoring the broad biological significance of this function. Understanding GO:0001918 therefore provides mechanistic insight into isoprenoid biology and offers a target for therapeutic intervention.
• Farnesylated protein binding enables membrane targeting of small GTPases such as Rheb, which is required for mTORC1 signaling and cell growth.
• It mediates polymerization and membrane binding of farnesylated human guanylate-binding protein 1 (hGBP1), a key player in host defense.
• Farnesyltransferase inhibitors like tipifarnib disrupt farnesylated protein interactions and prevent hypoxia-induced pulmonary hypertension.
• In acute myelogenous leukemia, tipifarnib inhibits Rheb prenylation and stabilizes Bax, linking farnesylated protein binding to apoptosis regulation.
• Plant ACBP2 binds the farnesylated protein AtFP6, connecting farnesylated protein binding to heavy-metal stress responses.
• Farnesylated protein binding is essential for proper subcellular localization of Ras family proteins, which are frequently mutated in cancer.
• The function is conserved across eukaryotes, from yeast to plants to humans, highlighting its fundamental role in cell biology.
• Studying farnesylated protein binding informs drug development targeting isoprenylation pathways.
• It contributes to the regulation of cell proliferation, survival, and differentiation through GTPase-mediated signaling.
• Farnesylated protein binding assays are used to screen for modulators of prenylation and protein-protein interactions.
What Happens During farnesylated protein binding?
Farnesylation of the target protein
In simple terms: First, a lipid tag called farnesyl is attached to the target protein.
Farnesylated protein binding begins with the post-translational attachment of a farnesyl group to a cysteine residue in the C-terminal CaaX motif of the target protein. This reaction is catalyzed by protein farnesyltransferase (FTase), a heterodimeric enzyme that uses farnesyl diphosphate as the isoprenoid donor. The farnesyl modification increases the hydrophobicity of the protein and primes it for membrane interaction and for recognition by binding partners. Without farnesylation, the target protein cannot engage in the specific binding events defined by GO:0001918.
Recognition and binding by the interacting protein
In simple terms: A partner protein recognizes the farnesyl tag and binds to it.
Once farnesylated, the target protein presents a unique surface that can be recognized by proteins with farnesylated protein binding activity. This recognition may involve the farnesyl lipid itself, the modified cysteine region, or a farnesylation-dependent conformational epitope. For example, farnesylated human guanylate-binding protein 1 (hGBP1) undergoes polymerization and membrane binding that depend on its farnesyl moiety, and specific binding interactions mediate these processes. The binding event is typically non-covalent and reversible, allowing dynamic regulation of complex formation.
Membrane association and complex assembly
In simple terms: Binding helps the farnesylated protein attach to membranes and form larger complexes.
Farnesylated protein binding often leads to membrane association, because the farnesyl group inserts into lipid bilayers and binding partners may further stabilize this interaction. In the case of farnesylated hGBP1, polymerization and membrane binding are coupled to its farnesylation status, and the binding of partner proteins can modulate these activities. Similarly, farnesylated small GTPases such as Rheb require membrane anchoring for signaling, and their interactions with binding proteins influence downstream pathways. This step is critical for spatial organization of signaling complexes.
Functional consequences and regulation
In simple terms: The binding changes what the cell does, and it can be turned on or off.
The functional outcomes of farnesylated protein binding include activation or inhibition of signaling cascades, altered protein stability, and changes in cellular responses such as proliferation or apoptosis. For instance, farnesyltransferase inhibitors like tipifarnib disrupt Rheb prenylation and stabilize Bax in acute myelogenous leukemia cells, showing that interfering with farnesylated protein interactions can shift cell fate. In pulmonary hypertension, tipifarnib prevents disease development by inhibiting farnesylation-dependent processes. These examples illustrate that farnesylated protein binding is a regulated and druggable node in disease pathways.
Key Genes Involved in GO:0001918 farnesylated protein binding
The following genes and proteins are experimentally linked to farnesylated protein binding or to the farnesylation machinery that generates its ligands.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FNTA | Alpha subunit of protein farnesyltransferase; catalyzes farnesyl transfer to CaaX proteins | Target for farnesyltransferase inhibitors; essential for generating farnesylated proteins |
| FNTB | Beta subunit of protein farnesyltransferase; contains the catalytic site | Determines substrate specificity and is studied in isoprenylation research |
| RHEB | Farnesylated small GTPase; activator of mTORC1 signaling | Farnesylation is required for its membrane localization and function; inhibited by tipifarnib |
| HRAS | Farnesylated small GTPase; proto-oncogene | Model for farnesylated protein binding and membrane targeting in cancer |
| KRAS | Farnesylated small GTPase; frequently mutated in cancers | Alternative prenylation pathways studied in the context of farnesyltransferase inhibitor resistance |
| NRAS | Farnesylated small GTPase; proto-oncogene | Used to study farnesyl-dependent interactions and signaling |
| GBP1 | Farnesylated guanylate-binding protein; polymerizes and binds membranes | Direct model for farnesylated protein binding and polymerization |
| ACBP2 | Arabidopsis acyl-CoA-binding protein; binds farnesylated AtFP6 | Plant model for farnesylated protein binding in heavy-metal response |
| AtFP6 | Farnesylated heavy-metal-binding protein in Arabidopsis | Interacts with ACBP2; studied for farnesylation-dependent binding |
| RAB | Family of small GTPases; some members are geranylgeranylated, others farnesylated | Relevant to prenylation-dependent trafficking and binding |
| RHO | Small GTPase family; prenylated for membrane localization | Studied in context of isoprenylated protein binding |
| CDC42 | Small GTPase; prenylated for function | Model for isoprenoid-dependent interactions |
| LAMIN B | Nuclear lamina protein; farnesylated in some contexts | Studied for farnesylation-dependent nuclear envelope interactions |
| PDE6D | Prenyl-binding protein; interacts with farnesylated proteins | Involved in trafficking of farnesylated cargo |
| RASGRP | Guanine nucleotide exchange factor; interacts with farnesylated Ras | Studied for farnesylation-dependent binding |
| CHP1 | Calcineurin homologous protein; may interact with farnesylated proteins | Potential binding partner in membrane trafficking |
| PRA1 | Prenylated Rab acceptor; binds prenylated proteins | Model for farnesylated protein binding in vesicle transport |
| RCE1 | CAAX protease; processes farnesylated proteins | Affects farnesylated protein binding by modifying C-terminus |
How Is farnesylated protein binding Regulated?
Farnesylated protein binding is regulated at multiple levels. The availability of farnesylated proteins is controlled by the mevalonate pathway, which supplies farnesyl diphosphate, and by the activity of protein farnesyltransferase. Mevalonate metabolites boost aged oocyte quality through prenylation of small GTPases, indicating that metabolic flux through this pathway modulates farnesylation and downstream binding events. Farnesyltransferase inhibitors such as tipifarnib reduce the pool of farnesylated proteins, thereby indirectly regulating binding interactions. Additionally, the binding affinity and specificity can be modulated by post-translational modifications of the binding partner, by lipid composition of membranes, and by accessory proteins that stabilize or disrupt complexes. In plants, the interaction between ACBP2 and farnesylated AtFP6 may be regulated by heavy-metal stress, suggesting environmental control of farnesylated protein binding.
farnesylated protein binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RHEB | Acute myelogenous leukemia; mTORC1 signaling | Knockout or point-mutation of farnesylation site in AML cell lines; tipifarnib treatment |
| HRAS | Cancer; Ras-driven proliferation | Knock-in of farnesylation-deficient HRAS in cancer cells; binding assays |
| KRAS | Cancer; farnesyltransferase inhibitor resistance | CRISPR knockout of farnesyltransferase in KRAS-mutant cells; prenylation analysis |
| GBP1 | Host defense; polymerization and membrane binding | Overexpression of farnesylated vs. non-farnesylated GBP1; polymerization assays |
| ACBP2/AtFP6 | Heavy-metal stress in plants | Arabidopsis knockout of ACBP2 or AtFP6; metal sensitivity assays |
Pulmonary hypertension
Farnesylated protein binding contributes to the pathogenesis of hypoxia-induced pulmonary hypertension. Tipifarnib, a farnesyltransferase inhibitor, prevents the development of this condition in experimental models, indicating that farnesylation-dependent interactions are required for disease progression. The mechanism likely involves small GTPases such as Rho and Ras, whose farnesylation and subsequent binding to effectors promote vascular remodeling.
Acute myelogenous leukemia
In acute myelogenous leukemia (AML), farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax, leading to apoptosis of leukemic cells. This links farnesylated protein binding to survival signaling and suggests that disrupting these interactions is a therapeutic strategy. Rheb is a farnesylated GTPase that activates mTORC1; its prenylation is necessary for membrane association and binding to downstream partners.
Cancer and Ras-driven malignancies
Ras family proteins (HRAS, KRAS, NRAS) are farnesylated and their membrane localization and interactions with effectors depend on this modification. Farnesylated protein binding is therefore central to oncogenic Ras signaling. However, KRAS and NRAS can also be geranylgeranylated, which limits the efficacy of farnesyltransferase inhibitors in some cancers. Understanding the binding interfaces of farnesylated Ras proteins may inform new therapeutic approaches.
Heavy-metal stress in plants
In Arabidopsis thaliana, the acyl-CoA-binding protein ACBP2 interacts with the heavy-metal-binding farnesylated protein AtFP6, demonstrating a role for farnesylated protein binding in plant stress responses. This interaction may help plants cope with heavy-metal exposure, and it highlights the evolutionary conservation of farnesylated protein recognition mechanisms.
From farnesylated protein binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does farnesylation of a candidate protein mediate its binding to a specific partner? | Point mutation of the CaaX cysteine to alanine (farnesylation-deficient) via CRISPR knock-in |
| What is the interactome of a farnesylated protein? | Knock-in of an epitope-tagged farnesylated protein followed by affinity purification and mass spectrometry |
| Is a gene required for farnesylated protein binding-dependent signaling? | CRISPR knockout of the gene in cell lines, followed by binding and functional assays |
| Can a disease-associated mutation alter farnesylated protein binding? | Knock-in of the patient mutation and comparison of binding affinity to wild type |
| Does overexpression of a farnesylated protein drive cellular transformation? | Overexpression of wild-type vs. farnesylation-deficient protein in primary or immortalized cells |
| What are the downstream transcriptional consequences of disrupting farnesylated protein binding? | RNA-seq after CRISPR knockout or point mutation of the farnesylated protein |
How to Study the farnesylated protein binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between proteins | Confirm binding of a candidate protein to a farnesylated partner |
| Pull-down assay | Binding affinity and specificity | Test direct interaction using purified farnesylated bait |
| Surface plasmon resonance | Kinetics and affinity of binding | Quantify real-time binding of farnesylated proteins |
| Fluorescence microscopy | Subcellular localization and co-localization | Visualize membrane association and complex formation |
| AP-MS | Interactome composition | Identify farnesylation-dependent binding partners |
| CRISPR knockout | Gene function and requirement | Abolish farnesylation or binding partner expression |
| Farnesyltransferase inhibitor treatment | Prenylation status and downstream effects | Pharmacological disruption of farnesylated protein binding |
| RNA-seq | Transcriptional consequences | Measure gene expression changes after perturbation |
Biochemical binding assays
In vitro binding assays such as pull-downs, co-immunoprecipitation, and surface plasmon resonance (SPR) are used to measure direct interactions between farnesylated proteins and their binding partners. Purification of farnesylated hGBP1 and characterization of its polymerization and membrane binding provide a template for such studies. These methods can quantify affinity and specificity and test the requirement for the farnesyl moiety.
Fluorescence microscopy and imaging
Live-cell imaging with fluorescently tagged farnesylated proteins and binding partners reveals subcellular localization, membrane association, and complex assembly. For example, imaging of farnesylated hGBP1 has been used to visualize polymerization and membrane binding. Co-localization studies can confirm whether binding occurs at specific organelles or membrane domains.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry (AP-MS) can identify the interactome of farnesylated proteins. By comparing wild-type and farnesylation-deficient baits, researchers can distinguish farnesylation-dependent interactions. This approach is valuable for discovering novel farnesylated protein binding partners and for mapping interaction networks.
Genetic and pharmacological perturbation
CRISPR knockout of farnesyltransferase subunits (FNTA, FNTB) or treatment with farnesyltransferase inhibitors such as tipifarnib can abolish farnesylation and thereby disrupt farnesylated protein binding. These perturbations, combined with phenotypic assays, establish causality. In plants, knockout of ACBP2 or AtFP6 can test the role of their interaction in heavy-metal stress.
How CRISPR Can Be Used to Study GO:0001918 farnesylated protein binding
Knockout
CRISPR knockout of genes encoding farnesylated proteins or their binding partners can definitively test the requirement for farnesylated protein binding in cellular processes. For example, knocking out FNTA or FNTB eliminates farnesylation and thus prevents binding events. Knockout of RHEB or GBP1 can reveal downstream phenotypes linked to farnesylated protein function. In plants, knockout of ACBP2 or AtFP6 can test their interaction in heavy-metal stress.
Point Mutation
Point mutation of the cysteine in the CaaX motif to alanine (e.g., C185A in some GTPases) prevents farnesylation and is a powerful way to study farnesylated protein binding. CRISPR knock-in of such point mutations allows comparison of wild-type and non-farnesylated proteins in the same cellular context. This approach has been used to show that farnesylation is required for Rheb function and for hGBP1 polymerization.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA, GFP) into endogenous loci of farnesylated proteins enables affinity purification and imaging of binding complexes at physiological expression levels. Tagged knock-in of GBP1 or Rheb can be used to isolate interacting proteins and to track localization. Knock-in of disease-associated mutations can also test their impact on farnesylated protein binding.
Overexpression
Overexpression of wild-type or farnesylation-deficient proteins is used to assess gain-of-function effects and to compare binding capacity. For example, overexpression of farnesylated hGBP1 drives polymerization, whereas non-farnesylated mutants do not. Overexpression can also sensitize cells to farnesyltransferase inhibitors, providing a model for drug testing.
How EDITGENE Supports farnesylated protein binding Research
Researchers studying farnesylated protein binding-related genes often need to determine whether a candidate gene is causally involved in a specific interaction or phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous interrogation of farnesylated protein binding mechanisms.
Contact EDITGENE today to design your custom CRISPR model for farnesylated protein binding research.
Frequently Asked Questions About farnesylated protein binding
What is farnesylated protein binding?
Farnesylated protein binding (GO:0001918) is a molecular function defined as binding to a farnesylated protein, i.e., a protein carrying a farnesyl lipid modification.
What genes are involved in farnesylated protein binding?
Genes include FNTA and FNTB (farnesyltransferase subunits), small GTPases such as RHEB, HRAS, KRAS, NRAS, and guanylate-binding proteins like GBP1, as well as plant genes ACBP2 and AtFP6.
How does farnesylation affect protein binding?
Farnesylation adds a hydrophobic lipid that promotes membrane association and creates or stabilizes binding interfaces, enabling specific protein-protein interactions.
What diseases are linked to farnesylated protein binding?
Pulmonary hypertension, acute myelogenous leukemia, and cancers driven by Ras family GTPases are linked to farnesylated protein interactions.
What is the role of farnesyltransferase in farnesylated protein binding?
Farnesyltransferase catalyzes the attachment of the farnesyl group to target proteins, thereby generating the farnesylated ligands that are recognized by binding partners.
How can I study farnesylated protein binding in the lab?
Common methods include co-immunoprecipitation, pull-down assays, surface plasmon resonance, fluorescence microscopy, and CRISPR-based perturbation of farnesylation.
What is the GO ID for farnesylated protein binding?
The Gene Ontology ID is GO:0001918, under the molecular_function aspect.
Can farnesyltransferase inhibitors block farnesylated protein binding?
Yes, inhibitors such as tipifarnib reduce the pool of farnesylated proteins, thereby indirectly disrupting farnesylated protein binding and downstream signaling.
Is farnesylated protein binding conserved in plants?
Yes, the interaction between Arabidopsis ACBP2 and the farnesylated protein AtFP6 demonstrates conservation of farnesylated protein binding in plants.
What experimental models are used to study farnesylated protein binding?
Models include CRISPR knockout and knock-in cell lines, overexpression systems, and biochemical assays with purified farnesylated proteins such as hGBP1.
Conclusion
Farnesylated protein binding (GO:0001918) is a fundamental molecular function that enables cells to recognize and respond to proteins carrying a farnesyl lipid modification. This function is critical for membrane targeting, complex assembly, and signaling by small GTPases and other farnesylated proteins, with direct implications for diseases such as pulmonary hypertension and leukemia. The interplay between farnesylation machinery, binding partners, and downstream effectors offers numerous targets for therapeutic intervention and basic research. By leveraging CRISPR-based knockout, point mutation, knock-in, and overexpression models, researchers can dissect the precise roles of farnesylated protein binding in health and disease. EDITGENE provides the tools and expertise to accelerate these discoveries.
References
- 1. Liu C et al.. 2025. Mevalonate metabolites boost aged oocyte quality through prenylation of small GTPases.. Nat Aging 5(10):2022-2038 PMID: 40858817
- 2. Duluc L et al.. 2017. Tipifarnib prevents development of hypoxia-induced pulmonary hypertension.. Cardiovasc Res 113(3):276-287 PMID: 28395021
- 3. Sistemich L et al.. 2020. The Molecular Mechanism of Polymer Formation of Farnesylated Human Guanylate-binding Protein 1.. J Mol Biol 432(7):2164-2185 PMID: 32087202
- 4. McTaggart SJ. 2006. Isoprenylated proteins.. Cell Mol Life Sci 63(3):255-67 PMID: 16378247
- 5. Gao W et al.. 2009. Arabidopsis thaliana acyl-CoA-binding protein ACBP2 interacts with heavy-metal-binding farnesylated protein AtFP6.. New Phytol 181(1):89-102 PMID: 18823312
- 6. Sistemich L et al.. 2020. Purification of Farnesylated hGBP1 and Characterization of Its Polymerization and Membrane Binding.. Methods Mol Biol 2159:67-81 PMID: 32529364
- 7. Ding H et al.. 2014. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.. Haematologica 99(1):60-9 PMID: 23996484
- 8. Park HW et al.. 1997. Protein farnesyltransferase.. Curr Opin Struct Biol 7(6):873-80 PMID: 9434909
